Hartmut Lode

Summary

Country: Germany

Publications

  1. ncbi Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval
    H Lode
    HELIOS Klinikum Emil von Behring, Zum Heckeshorn 33, D 14109 Berlin, Germany
    Eur Respir J 24:947-53. 2004
  2. ncbi Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy subjects aged 70 years or older
    H Lode
    Research Centre for Medical Studies, Institute of Clinical Pharmacology, Charite Universitatsmedizin Berlin, Hohenzollerndamm 2, Berlin, Germany
    Vaccine 29:4940-6. 2011
  3. ncbi Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia
    H Lode
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, affil Freie Universität Berlin, Berlin, Germany
    Clin Microbiol Infect 10:512-20. 2004
  4. ncbi A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia
    H Lode
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, affil Freie Universität Berlin, Berlin, Germany
    Clin Microbiol Infect 10:403-8. 2004
  5. ncbi Recent developments in antibiotic treatment
    Andres De Roux
    Department for Immunology and Infectious Diseases Pneumologie I, City Hospital Heckeshorn, Zentralklinik Emil von Behring, Affil Free University Berlin, Zum Heckeshorn 33, 14109 Berlin, Germany
    Infect Dis Clin North Am 17:739-51. 2003
  6. ncbi Gemifloxacin for community-acquired pneumonia
    Hartmut M Lode
    RCMS, Hohenzollerndamm 2, Ecke Bundesallee, D 10717 Berlin Wilmersdorf, Germany
    Expert Opin Investig Drugs 17:779-86. 2008
  7. ncbi [Problems of pharmacotherapy of infections in the aged]
    A Kuhnke
    Abteilung für Lungen und Infektionskrankheiten, Zentralklinik Emil von Behring, Akademisches Lehrkrankenhaus, Freien Universitat Berlin
    Internist (Berl) 44:986-94. 2003
  8. ncbi Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia
    H Lode
    Zentralklinik Emil von Behring, Lungenklinik Heckeshorn, Berlin 10115, Germany
    Respir Med 97:1134-42. 2003
  9. ncbi Role of newer fluoroquinolones in lower respiratory tract infections
    H Lode
    Department of Chest and Infectious Diseases, Chest Hospital Heckershorn, Central Clinic Emil von Behring, Zum Heckeshorn 33, 14109 Berlin, Germany
    J Antimicrob Chemother 50:151-4. 2002
  10. ncbi Management of serious nosocomial bacterial infections: do current therapeutic options meet the need?
    H Lode
    Department of Chest and Infectious Diseases, Helios Klinikum E v Behring, Teaching Hospital Charité Berlin, Berlin, Germany
    Clin Microbiol Infect 11:778-87. 2005

Collaborators

Detail Information

Publications74

  1. ncbi Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval
    H Lode
    HELIOS Klinikum Emil von Behring, Zum Heckeshorn 33, D 14109 Berlin, Germany
    Eur Respir J 24:947-53. 2004
    ..In summary, levofloxacin was associated with a significantly higher bacteriological eradication rate but similar exacerbation-free interval in patients with chronic obstructive pulmonary disease exacerbation compared to clarithromycin...
  2. ncbi Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy subjects aged 70 years or older
    H Lode
    Research Centre for Medical Studies, Institute of Clinical Pharmacology, Charite Universitatsmedizin Berlin, Hohenzollerndamm 2, Berlin, Germany
    Vaccine 29:4940-6. 2011
    ..Local reactions for the 4 × dose, but not the 2 × dose, were statistically significantly higher than for the 1 × dose. No treatment-related serious adverse events occurred...
  3. ncbi Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia
    H Lode
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, affil Freie Universität Berlin, Berlin, Germany
    Clin Microbiol Infect 10:512-20. 2004
    ..Overall, this study showed that gatifloxacin was equivalent clinically to a standard course of co-amoxiclav in patients with community-acquired pneumonia, and that gatifloxacin was safe and well-tolerated...
  4. ncbi A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia
    H Lode
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, affil Freie Universität Berlin, Berlin, Germany
    Clin Microbiol Infect 10:403-8. 2004
    ..Oral gatifloxacin 400 mg once-daily appeared to be a safe and effective alternative to clarithromycin in the treatment of community-acquired pneumonia...
  5. ncbi Recent developments in antibiotic treatment
    Andres De Roux
    Department for Immunology and Infectious Diseases Pneumologie I, City Hospital Heckeshorn, Zentralklinik Emil von Behring, Affil Free University Berlin, Zum Heckeshorn 33, 14109 Berlin, Germany
    Infect Dis Clin North Am 17:739-51. 2003
    ..No antibiotic, regardless of its potency, can free the clinician from keeping the difficult balance between individual undertreatment and general overtreatment...
  6. ncbi Gemifloxacin for community-acquired pneumonia
    Hartmut M Lode
    RCMS, Hohenzollerndamm 2, Ecke Bundesallee, D 10717 Berlin Wilmersdorf, Germany
    Expert Opin Investig Drugs 17:779-86. 2008
    ..Gemifloxacin is one of the newest members of this class of antibiotics and has performed favourably in this indication...
  7. ncbi [Problems of pharmacotherapy of infections in the aged]
    A Kuhnke
    Abteilung für Lungen und Infektionskrankheiten, Zentralklinik Emil von Behring, Akademisches Lehrkrankenhaus, Freien Universitat Berlin
    Internist (Berl) 44:986-94. 2003
    ..Especially the newer antibiotics Ertapenem, Linezolid, Quinupristin/Dalfopristin and Telithromycin are discussed in detail...
  8. ncbi Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia
    H Lode
    Zentralklinik Emil von Behring, Lungenklinik Heckeshorn, Berlin 10115, Germany
    Respir Med 97:1134-42. 2003
    ..IV/PO moxifloxacin was evaluated in the treatment of hospitalized patients with severe community-acquired pneumonia (CAP)...
  9. ncbi Role of newer fluoroquinolones in lower respiratory tract infections
    H Lode
    Department of Chest and Infectious Diseases, Chest Hospital Heckershorn, Central Clinic Emil von Behring, Zum Heckeshorn 33, 14109 Berlin, Germany
    J Antimicrob Chemother 50:151-4. 2002
  10. ncbi Management of serious nosocomial bacterial infections: do current therapeutic options meet the need?
    H Lode
    Department of Chest and Infectious Diseases, Helios Klinikum E v Behring, Teaching Hospital Charité Berlin, Berlin, Germany
    Clin Microbiol Infect 11:778-87. 2005
    ..The development of novel and effective alternative agents, such as tigecycline, is therefore important...
  11. ncbi Vasculitis and infection: effects of immunosuppressive therapy
    H M Lode
    Department of Chest and Infectious Diseases, Helios Klinikum Emil von Behring affil Charité Universitätsmedizin, Berlin, Germany
    Clin Nephrol 64:475-9. 2005
    ..The contribution of infections to the mortality of vasculitis patients is important and should induce early and careful control of these events...
  12. ncbi [Management of community-acquired pneumonia in the physician's office]
    H M Lode
    HELIOS Klinikum Emil von Behring, Department Lungenklinik Heckeshorn
    MMW Fortschr Med 148:32-5. 2006
    ....
  13. ncbi Moxifloxacin: update and perspectives after 8 years of usage
    Hartmut M Lode
    RCMS Institute for Clinical Pharmacology, , Hohenzollerndamm 2, D10717 Berlin, Germany
    Expert Rev Respir Med 2:443-53. 2008
    ..The most recent studies covering these clinical indications are discussed...
  14. ncbi Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections
    Hartmut Lode
    City Hospital Berlin Zehlendorf, Free University of Berlin, Berlin, Germany
    Am J Med 123:S26-38. 2010
    ....
  15. ncbi Clinical impact of antibiotic-resistant Gram-positive pathogens
    H M Lode
    Research Centre for Medical Studies, Affiliated Institute for Clinical Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Microbiol Infect 15:212-7. 2009
    ..This review addresses the impact of antibiotic-resistant Gram-positive pathogens on clinical outcomes...
  16. ncbi Rational antibiotic therapy and the position of ampicillin/sulbactam
    Hartmut M Lode
    Research Centre for Medical Studies, Institute of Clinical Pharmacology, Charite Universitatsmedizin Berlin, Hohenzollerndamm 2, Berlin, Germany
    Int J Antimicrob Agents 32:10-28. 2008
    ..This is also recognised in recent published national and international guidelines, many of which recommend ampicillin/sulbactam as first-line therapy for various respiratory and skin infections...
  17. ncbi Optimising outcomes of hospital infections through appropriate empirical antimicrobial therapy. Introduction
    H Lode
    Research Center for Medical Studies, Institute for Clinical Pharmacology and Toxicology, , Berlin, Germany
    Clin Microbiol Infect 14:1-2. 2008
  18. ncbi A prediction model for bacterial etiology in acute exacerbations of COPD
    H Lode
    HELIOS Klinikum Emil von Behring, affiliated Free University Berlin, Chest Hospital Heckeshorn Infectious Disease and Immunology, Zum Heckeshorn 33, 14109, Berlin, Germany
    Infection 35:143-9. 2007
    ..We developed a prediction model for infection with gram-negative enteric bacteria (GNEB) and Pseudomonas aeruginosa...
  19. ncbi Managing community-acquired pneumonia: a European perspective
    Hartmut M Lode
    Research Center for Medical Studies RCMS, Institute for Clinical Pharmacology, Charite Universitatsmedizin Berlin, Hohenzollerndamm 2, Ecke Bundesallee, D 10717 Berlin Wilmersdorf, Germany
    Respir Med 101:1864-73. 2007
    ..The emergence and spread of resistance to commonly used antibiotics has challenged the management of CAP. Multiple sets of CAP guidelines have been published to address the continued changes in this complex disease...
  20. ncbi [Uses in in ambulatory and stationary situations. Clinical indications for beta lactams]
    Hartmut M Lode
    Research Center for Medical Studies, ,
    Pharm Unserer Zeit 35:428-31. 2006
  21. ncbi Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical effic
    Hartmut Lode
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, Akademisches Lehrkrankenhaus, Free University Berlin, Berlin, Germany
    Clin Ther 24:1915-36. 2002
    ....
  22. ncbi [Antimycotic treatment of pulmonary aspergilloma in patients without neutropenia]
    H Grysczyk
    Abteilung für Pneumologie und Infektiologie, Lungenklinik Heckeshorn, Zentralklinik Emil von Behrin, Germany
    Dtsch Med Wochenschr 127:492-6. 2002
    ..Pulmonary aspergillomas are associated with a high morbidity and mortality. There are only very few data about non-surgical treatment in immunocompetent patients...
  23. ncbi Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species
    H F Geerdes-Fenge
    Department of Pulmonary and Infectious Diseases, Freie Universitat Berlin, 14109 Berlin, Germany
    Antimicrob Agents Chemother 44:3478-80. 2000
    ....
  24. ncbi Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections
    H Lode
    Pneumologie I Infektiologie and Immunologie, Lungenklinik Heckeshorn, Zum Heckeshorn 33, 14109 Berlin, Germany
    Int J Antimicrob Agents 18:199-209. 2001
    ....
  25. ncbi Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint
    H Lode
    Department of Chest and Infectious Diseases, Emil von Behring Hospital, Berlin, Germany
    Chemotherapy 47:24-31; discussion 44-8. 2001
    ..Moxifloxacin is currently under observation concerning QTc effects. Levofloxacin has no QTc prolongation and a very low phototoxic potential, making it one of the safest new fluoroquinolones...
  26. ncbi In vitro effects of interleukin-10, prednisolone, and GM-CSF on the non-specific immune function of human polymorphonuclear leucocytes and monocytes
    S U Ziege
    Department of Chest and Infectious Diseases, City Hospital Zehlendorf Heckeshorn, Berlin, Germany
    Eur J Med Res 5:369-74. 2000
    ..66. 9 +/- 14.2%, p = 0.0019). In contrast to prednisolone, neither MON nor PMN chemotaxis was suppressed by IL-10. In conclusion, IL-10 had only marginal immunosuppressive effects on the unspecific immunity compared to prednisolone...
  27. ncbi Role of newer fluoroquinolones in lower respiratory tract infections
    H Lode
    Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn, Central Clinic Emil von Behring, Zum Heckeshorn 33, 14109 Berlin, Germany
    J Antimicrob Chemother 49:709-12. 2002
  28. ncbi [Infections caused by Stenotrophomonas maltophilia (SMA) in intensive care patients--a prospective case-control study]
    M Raffenberg
    Lungenklinik Heckeshorn, Zentralklinik Emil von Behring, Akademisches Lehrkrankenhaus der Freien Universität Berlin
    Dtsch Med Wochenschr 126:514-8. 2001
    ..The importance of Stenotrophomonas maltophilia (SMA) as an etiologic frequently polyresistant pathogen in severe nosocomial infections has increased...
  29. ncbi Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces
    Olaf Burkhardt
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, Berlin, Germany
    Scand J Infect Dis 34:898-903. 2002
    ..8. Pharmacokinetic parameters of clarithromycin and its metabolite, 14-hydroxy-clarithromycin, were similar to previously published data. Accumulation was found. No serious adverse events were observed with either study drug...
  30. ncbi Treatment of pneumonia in elderly patients
    Malina Schmidt-Ioanas
    HELIOS Klinikum Emil von Behring, Department of Chest and Infectious Diseases, Lungenklinik HeckeshornZum Heckeshorn, 3314109 Berlin, Germany
    Expert Opin Pharmacother 7:499-507. 2006
    ..Antimicrobial therapy should take into account the most recent guidelines, which are briefly presented in this review. A special consideration should be given to the preventive measures, including vaccination, oral care and nutrition...
  31. ncbi New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient
    Malina Schmidt-Ioanas
    HELIOS Klinikum Emil von Behring, Berlin, Germany
    Curr Opin Crit Care 11:481-6. 2005
    ..No dramatic superiority of the new drugs in comparison to the standard therapies was observed in most of the clinical trials. Better results on the efficacy of the drugs under investigation are expected...
  32. ncbi Beau's lines in a patient treated with moxifloxacin for anaerobic pulmonary infection
    Olaf Burkhardt
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, Berlin, Germany
    Scand J Infect Dis 35:516-8. 2003
    ..The appearance and circumstances of this nail disorder were consistent with the diagnosis of Beau's lines...
  33. ncbi Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study
    Mathias W R Pletz
    Department of Chest and Infectious Diseases, City Hospital Emil von Behring Chest Hospital Heckeshorn, Germany
    Antimicrob Agents Chemother 48:780-2. 2004
    ..209 and 0.273 log(10) CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid...
  34. ncbi [MRSA (methicillin-resistant Staphylococcus aureus) infections in patients with pulmonary diseases]
    R Erbes
    Lungenklinik Heckeshorn, Krankenhaus Zehlendorf, Berlin
    Pneumologie 50:706-11. 1996
    ..MRSA-infection in pulmonary medicine emerged as a problem mostly in patients with multimorbidity and severe underlying diseases. Change of resistance in strains and new strains were observed...
  35. ncbi Apoptosis of peripheral blood neutrophils in COPD exacerbation does not correlate with serum cytokines
    Malina Schmidt-Ioanas
    Department of Chest and Infectious Diseases, HELIOS Klinikum Emil von Behring, Zum Heckeshorn 33, 14109 Berlin, Germany
    Respir Med 100:639-47. 2006
    ..No relationship could be found between the reduced percentage of apoptotic neutrophils in blood and serum concentration of IL-6, IL-8 and TNF-alpha or other clinical parameters in patients with COPD exacerbation...
  36. ncbi Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers
    Olaf Burkhardt
    Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn, , Zum Heckeshorn 33, D-14109 Berlin, Germany
    J Antimicrob Chemother 50:707-12. 2002
    ..01). Pharmacokinetic parameters of amoxicillin and clavulanic acid found in this study were similar to previously published data. No accumulation was found with co-amoxiclav. No serious adverse event was observed with the study drugs...
  37. ncbi Synergistic effects of dexamethasone and quinolones on human-derived tendon cells
    Judith Sendzik
    Institute of Clinical Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Garystr 5, 14195 Berlin, Germany
    Int J Antimicrob Agents 35:366-74. 2010
    ..The clinical observations of an increased risk of quinolone-induced tendinopathy by glucocorticoids are supported by these in vitro data...
  38. ncbi The impersonator
    Hartmut Lode
    , Berlin, Germany
    Am J Med 120:239-41. 2007
  39. ncbi Ultrastructural types of alveolar macrophages in bronchoalveolar lavages from patients with pulmonary sarcoidosis
    Olaf Burkhardt
    Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn, Berlin, Germany
    Micron 38:572-9. 2007
    ..Numerous electron-dense inclusions in type III also indicate an increased macrophage activity that leads to an increased release of cytokines, which in turn can trigger an inflammatory reaction...
  40. ncbi Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care
    R Erbes
    HELIOS Klinikum Emil von Behring, Zum Heckeshorn 33, D 14109 Berlin, Germany
    Eur Respir J 27:1223-8. 2006
    ..These data indicate a high mortality of patients with tuberculosis requiring intensive care unit care and identifies new independently associated risk factors...
  41. ncbi Effect of calcium carbonate on bioavailability of orally administered gemifloxacin
    M W Pletz
    Department of Chest and Infectious Diseases, City Hospital E v Behring, Free University of Berlin, Germany
    Antimicrob Agents Chemother 47:2158-60. 2003
    ..33 h; and area under the concentration-time curve from 0 h to infinity (AUC( infinity )), 6.79 microg. h/ml. Only simultaneous coadministration of calcium carbonate reduced C(max) (-17%) and AUC( infinity ) (-21%) significantly...
  42. ncbi Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess
    S R Ott
    Helios Chest Hospital Heckeshorn, Department of Chest and Infectious Diseases, Affiliated to Charité, University of Medicine Berlin, Walterhöfer Str 11, D 14165, Berlin, Germany
    Infection 36:23-30. 2008
    ..An antibiotic therapy, also covering anaerobic pathogens, is the treatment of choice. In this study we compared moxifloxacin (MXF) and ampicillin/sulbactam (AMP/SUL) concerning efficacy and safety in the treatment of AP and PLA...
  43. ncbi Safety considerations of fluoroquinolones in the elderly: an update
    Ralf Stahlmann
    Institute of Clinical Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Drugs Aging 27:193-209. 2010
    ..Because of physiological changes in renal function and when certain co-morbidities are present, some special considerations are necessary when elderly patients are treated with these drugs...
  44. ncbi What drives our choices? Evidence, guidelines or habit?
    Hartmut Lode
    Institute for Clinical Pharmacology, Charite Universitatsmedizin Berlin, Germany
    Int J Antimicrob Agents 29:S17-22. 2007
    ..Additional factors that should also influence this decision are physicians' prior experience and the individual patient's circumstances...
  45. ncbi Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration
    Dagmar Mainz
    Department of Chest and Infectious Diseases, Hospital Heckeshorn-Zehlendorf, Berlin, Germany
    J Antimicrob Chemother 50:699-706. 2002
    ..These effects were not so pronounced as to have any therapeutic influence, making dosage adjustment unnecessary...
  46. ncbi Fluoroquinolones in the elderly: safety considerations
    Ralf Stahlmann
    Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universitat Berlin, Berlin, Germany
    Drugs Aging 20:289-302. 2003
    ..Because of physiological changes in renal function and in case of certain comorbidities, some special considerations are necessary when fluoroquinolones are used to treat elderly patients...
  47. ncbi [Inpatient treatment costs of exacerbated chronic obstructive lung disease]
    K Riecke
    Abteilung fur Pneumologie, Infektiologie und Immunologie, Lungenklinik Heckeshorn, Berlin
    Pneumologie 53:199-206. 1999
    ..The proportion of the pharmacy expenditures was rather small, and hence this is not a primary target for the realisation of major savings...
  48. ncbi Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora
    H Lode
    Hospital Heckeshorn, , Germany
    Scand J Infect Dis 33:899-903. 2001
    ..The administration of linezolid mainly had an impact on the gram-positive bacteria and linezolid thus had an ecological profile different from that of amoxicillin/clavulanic acid...
  49. ncbi Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers
    A Lubasch
    Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn, Free University of Berlin, Berlin, Germany
    Antimicrob Agents Chemother 44:2600-3. 2000
    ..The five recently developed fluoroquinolones (gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin) showed greater bioavailability, longer half-lives, and higher C(max)s than ciprofloxacin...
  50. ncbi Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers
    A Lubasch
    Zentralklinik Emil v. Behring, Lungenklinik Heckeshorn, Department of Chest and Infectious Diseases, Berlin, Germany
    Clin Microbiol Infect 9:670-7. 2003
    ..However, for P. aeruginosa, the bactericidal activity of cepefime alone was higher than that of the combination with trovafloxacin...
  51. ncbi Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone
    U K Buchwald
    Department of Chest and Infectious Diseases, City Hospital Heckeshorn Zehlendorf, Zum Heckeshorn 33, D 14109 Berlin, Germany
    Eur J Med Res 4:85-94. 1999
    ..Our study indicates that IL-10 can behave as a de-activator as well as an activator on the non-specific immune system, depending on the cell type and the concentration...
  52. ncbi Improving care for patients with respiratory tract infections
    H Lode
    Zentralklinik Emil von Behring, Lungenklinik Heckeshorn, Akademisches Lehrkrankenhaus der FU Berlin, Germany
    J Chemother 14:22-8. 2002
    ..Accordingly, this paper focuses on the clinical trial data currently available...
  53. ncbi Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis
    Annette Lubasch
    Zentralklinik Emil v. Behring, Department Lungenklinik Heckeshorn, Pneumologie I, , Zum Heckeshorn 33, D-14109 Berlin
    J Antimicrob Chemother 51:659-64. 2003
    ....
  54. ncbi [Serologic early diagnosis of pneumonia caused by Mycoplasma pneumoniae]
    M Schmidt-Ioanas
    Pneumologische Abteilung I, HELIOS Klinikum Emil von Behring, Lungenklinik Heckeshorn
    Dtsch Med Wochenschr 131:613-7. 2006
    ..The study aimed to determine if a single serological test within the first days of hospital admission may be relevant for the diagnosis of community-acquired pneumonia (CAP) caused by M. pneumoniae...
  55. ncbi Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess
    M Allewelt
    Chest Hospital Heckeshorn, affiliated to Free University of Berlin, Berlin, Germany
    Clin Microbiol Infect 10:163-70. 2004
    ..Ampicillin + sulbactam and clindamycin +/- cephalosporin were both well-tolerated and proved equally effective in the treatment of aspiration pneumonia and lung abscess...
  56. ncbi Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers
    M Eisenblatter
    Institute for Microbiology and Hygiene, Charite University Medicine Berlin, Campus Benjamin Franklin, Free University and Humboldt University Berlin, Berlin, Germany
    Eur J Clin Microbiol Infect Dis 27:1087-92. 2008
    ..Temporal differential effects of azithromycin and clarithromycin on the induction of resistance were observed and need to be investigated regarding their effect on co-colonizing pathogens...
  57. ncbi ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate
    M W Pletz
    Department of Chest and Infectious Diseases, E. von Behring City Hospital, Free University of Berlin, Germany
    Antimicrob Agents Chemother 47:1129-31. 2003
    ..h/ml. Coadministration of ranitidine, reduced the C(max) (-25.7%) and AUC(0- infinity ) (-15.8%) significantly. Sucralfate had no impact on the bioavailability of ABT-773...
  58. ncbi Determination of trovafloxacin in human body fluids by high-performance liquid chromatography
    K Borner
    Institute for Clinical Chemistry and Pathobiochemistry, , , Germany
    J Chromatogr A 846:175-80. 1999
    ..Trovafloxacin was sufficiently separated from endogenous compounds. Results of validation are given. The method was applied successfully to a study of healthy volunteers...
  59. ncbi Electron microscopic findings in BAL of a fire-eater after petroleum aspiration
    Olaf Burkhardt
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, Berlin, Germany
    Chest 124:398-400. 2003
    ..Despite a large and necrotizing infiltration of the right lower lobe, the clinical course was uneventful with complete recovery...
  60. ncbi Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data
    Judith Sendzik
    Institut fur Klinische Pharmakologie und Toxikologie, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Berlin, Germany
    Int J Antimicrob Agents 33:194-200. 2009
    ..complicated urinary tract infections and enteritis caused by invasive multidrug-resistant pathogens (e.g. Salmonella, Shigella)...
  61. ncbi Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production
    T Schaberg
    Department of Pulmonary Medicine, City Hospital Berlin Zehlendorf, Germany
    Am Rev Respir Dis 146:1287-93. 1992
    ..The increased binding of smoker AM to endothelial cells could be inhibited by treating the HUVEC with a mAB against ICAM-1. The mAB anti-CD18 reduced O2- release from smoker AM by 42 +/- 5% after 120 min.(ABSTRACT TRUNCATED AT 250 WORDS)..
  62. ncbi [Diagnosis and therapy of abscess forming pneumonia]
    M Allewelt
    Zentralklinik Emil von Behring, Department Lungenklinik Heckeshorn, ,
    Ther Umsch 58:599-603. 2001
    ..g. recurrent severe hemoptysis, empyema or broncho-pleural fistula...
  63. ncbi [Changes in the spectrum of the causative agents of community-acquired pneumonias (1982-1992)]
    M Allewelt
    Pneumologische Abteilung L, Lungenklinik Heckeshorn, Krankenhaus Zehlendorf, Berlin
    Dtsch Med Wochenschr 122:1027-32. 1997
    ..The picture of pneumonia acquired out of hospital is continually changing. Microbial aetiology as well as predisposing factors, course and prognosis of this disease were prospectively analysed over a period of 10 years...
  64. ncbi Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells
    T Schaberg
    Department of Pulmonary Medicine, Chest Hospital Heckeshorn Zehlendorf, Berlin, Germany
    Am Rev Respir Dis 147:1507-13. 1993
    ..Our data indicate that the increased expression of LeuCAM on AM in subjects with SA and IPF seems to be involved in the increased O2- production of these cells in both diseases...
  65. ncbi Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy
    A Lubasch
    Dept of Chest and Infectious Diseases, Chest Hospital Heckeshorn, Berlin, Germany
    Eur Respir J 17:641-6. 2001
    ..In summary, sparfloxacin proved an effective and safe alternative antituberculosis drug for complicated tuberculosis...
  66. ncbi Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis
    A Polzin
    Dept of Chest and Infectious Diseases, City Hospital Emil von Behring, Free University of Berlin, Berlin, Germany
    Eur Respir J 21:939-43. 2003
    ....
  67. ncbi [Pulmonary melioidosis in a German Southeast Asia tourist]
    K Riecke
    , Immunologie und Laboratoriums-medizin, Lungenklinik Heckeshorn, Berlin
    Pneumologie 51:499-502. 1997
    ..CONCLUSION: For travellers and immigrants from Southeast Asia presenting smouldering infiltrations of the upper lobes, one should include Melioidosis in the differential diagnosis...
  68. ncbi [Chronic eosinophilic pneumonia]
    M Voss
    Pneumologische Abteilung I, Lungenklinik Heckeshorn, Berlin
    Dtsch Med Wochenschr 129:1858-60. 2004
    ..In some cases it may be necessary to continue steroid treatment over long periods, even years, to bring the pulmonary changes of CEP under control...
  69. ncbi Determination of linezolid in human serum and urine by high-performance liquid chromatography
    K Borner
    Institute for Clinical Chemistry and Pathobiochemistry, Benjamin Franklin University Hospital, Free University Berlin, Hindenburgdamm 30, D-12200 Berlin, Germany
    Int J Antimicrob Agents 18:253-8. 2001
    ..Comparison of HPLC results with results obtained using a quantitative microbiological assay yielded acceptable agreement both for serum and urine. The method was successfully used in a pharmacokinetic study with human volunteers...
  70. ncbi [Complex choices in respiratory tract infections: the search for simple solutions]
    K Klugman
    Research Center for Medical Studies, Institute for Clinical Pharmacology, , Hohenzollerndamm 2, D 10717 Berlin, Allemagne
    Med Mal Infect 37:1. 2007
  71. ncbi Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids
    A de Roux
    Department of Chest and Infectious Diseases, City Hospital Heckeshorn, Free University Berlin, Germany
    Respir Med 98:1187-94. 2004
    ..CONCLUSIONS: Systemic steroids did not influence the AB-response. In all groups mean AB-concentration increased significantly after vaccination but an important percentage of subjects of all three groups were non-responders...
  72. ncbi [Fever of unknown origin in the 21st century. 2. Non-infectious diseases (autoimmune diseases)]
    T Schneider
    Medizinische Klinik 1 (Gastroenterologie, Infektiologie und Rheumatologie, , Campus Benjamin Franklin, Berlin
    Dtsch Med Wochenschr 130:2774-8. 2005
  73. ncbi Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients
    A de Roux
    Department of Chest and Infectious Diseases, Heckeshorn, Helios Kliniken Emil von Behring, Berlin, Germany
    Vaccine 24:1537-42. 2006
    ..Systemic steroids did not influence the antibody response towards the MF59-adjuvanted influenza vaccine. We found that the strains included in the vaccine showed varying long-term immunogenicity...
  74. ncbi [Pneumocystis jiroveci pneumonia in immunocompromised patients without AIDS -- a case series]
    T Blum
    Klinik für Pneumologie und Infektiologie, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring
    Dtsch Med Wochenschr 131:1515-20. 2006
    ..We report on cases of Pneumocystis jiroveci pneumonia (PcP) (n = 1921) without associated AIDS in a chest hospital...